drugset / Trial / NCT02189941

Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers

NCT02189941

Phase 1 Completed 11 enrolled ApoPharma
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study was to evaluate the pharmacokinetic and safety profile of the sustained-release formulation of deferiprone under both fasting and fed conditions, and evaluate the relative bioavailability of this sustained-release formulation when compared to immediate-release formulation of deferiprone under fasting conditions.

Timeline

Start
2014-05
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 1000 mg
Subject Deferiprone Small molecule 2000 mg

Indications

No indication recorded.